Adipotide
Animal / preclinicalAlso known as: FTPP, Prohibitin-targeting peptide
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
An experimental targeted peptide designed to kill the blood supply of fat tissue. It produced weight loss in obese primates but also caused kidney toxicity, and it has not progressed to approved human use.
Mechanism
Homes to a marker on the vasculature supplying white fat and triggers apoptosis there, reducing fat mass in animal models.
Evidence
Concerning: primate studies showed weight loss but also dose-dependent kidney damage; there is no established safe human use.
Community-reported information
Not presented as a range. The documented nephrotoxicity signal makes community-style dosing information inappropriate to show.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Not well characterised in humans.
Storage
Refrigerate.
Commonly reported side effects
- Kidney toxicity (seen in primate studies)
- Dehydration
- Not characterised for safe human use
Legal status by region
- USNot FDA-approved; experimental with known toxicity signals.
Legal status changes over time; verify locally before relying on this.